SIRT2-IN-9

SIRT2-IN-9 (compound 12) is a selective inhibitor of SRIT2 with an IC50 value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer[1].

Signaling Pathways >> Epigenetics >> Sirtuin

Research Areas >> Cancer

Signaling Pathways >> Cell Cycle/DNA Damage >> Sirtuin

SIRT2:1.3 μM (IC50)

SIRT1:＞300 μM (IC50)

SIRT3:＞300 μM (IC50)

SIRT2-IN-9 (1-100 μM; 15 min) dose-dependently inhibits SRIT2 with an IC50 value of 1.3 μM, and inhibits SRIT1 and SRIT3 with IC50s ＞300 μM[1]. SIRT2-IN-9 (0-50 μM; 72 h) affects cell viability of MCF-7 cells[1]. SIRT2-IN-9 (0-50 μM; 6 h) affects acetylation of α-tubulin protein[1]. Cell Proliferation Assay[1] Cell Line: MCF-7 breast cancer cell line Concentration: 0-50 μM Incubation Time: 72 hours Result: Dose-dependently inhibited cell proliferation of MCF-7 breast cancer cells. Western Blot Analysis[1] Cell Line: MCF-7 breast cancer cell line Concentration: 6.25, 12.5, 25 and 50 μM Incubation Time: 6 hours Result: Dose-dependently increased acetylation of α-tubulin protein.

[1]. Yang SY, Li LL. The purposes of 5H- [1,2,4] triazine [5,6-b] indole derivatives of 3 substitutions. CN108309982A. 2017.